Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05029635

Phase III Study on HMPL-523 for Treatment of ITP

Primary Immune Thrombocytopenia (ITP) Clinical Trial

Official title:
A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HMPL-523 in Treatment of Primary Immune Thrombocytopenia (ITP) in Adults(ESLIM-01 Study)

Clinical Trial Summary

The purpose of this study is to determine whether HMPL-523 (sovleplenib) is safe and effective in the treatment of chronic Immune Thrombocytopenic Purpura (ITP).

Clinical Trial Description

This is a randomized, double-blind, placebo-controlled phase III clinical trial in adult patients with primary immune thrombocytopenia to determine whether HMPL-523 (sovleplenib) is safe and effective in the treatment of chronic Immune Thrombocytopenic Purpura (ITP) ;

Study Design

Related Conditions & MeSH terms

  • Primary Immune Thrombocytopenia (ITP)
  • Purpura, Thrombocytopenic, Idiopathic
  • Thrombocytopenia
Clinical Trial Details
NCT number NCT05029635
Study type Interventional
Source Hutchmed
Contact
Status Active, not recruiting
Phase Phase 3
Start date October 27, 2021
Completion date December 30, 2023
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04812483 - Immunomodulation With Eltrombopag in ITP Phase 2
Completed NCT06408324 - Evaluation of the Use of Thrombopoietin Receptor Agonists in Adults With Primary ITP in Europe
Recruiting NCT05338190 - Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia Phase 3
Completed NCT02042560 - Study of Immune Thrombocytopenia Pathogenesis: N/A
Recruiting NCT05653349 - Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) Phase 3
Withdrawn NCT04274452 - A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP) Phase 3
Recruiting NCT05718856 - TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP) Phase 4
Recruiting NCT05885555 - A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies Phase 2
Recruiting NCT04518475 - Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults Phase 4